Related references
Note: Only part of the references are listed.Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
Eugenio Mercuri et al.
LANCET NEUROLOGY (2021)
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Deepa Chand et al.
JOURNAL OF HEPATOLOGY (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
John W. Day et al.
LANCET NEUROLOGY (2021)
Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit
Meaghan Van Alstyne et al.
NATURE NEUROSCIENCE (2021)
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
Jerry R. Mendell et al.
JAMA NEUROLOGY (2021)
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
John W. Day et al.
DRUG SAFETY (2021)
Postmortem Analysis in a Clinical Trial of AAV2-NGF Gene Therapy for Alzheimer's Disease Identifies a Need for Improved Vector Delivery
Michael J. Castle et al.
HUMAN GENE THERAPY (2020)
Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model
Lei Sheng et al.
NUCLEIC ACIDS RESEARCH (2020)
Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
Amy G. Feldman et al.
JOURNAL OF PEDIATRICS (2020)
Conditional deletion of SMN in cell culture identifies functional SMN alleles
Anton J. Blatnik et al.
HUMAN MOLECULAR GENETICS (2020)
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Eloise Hudry et al.
NEURON (2019)
The Classical Complement Pathway Mediates Microglia-Dependent Remodeling of Spinal Motor Circuits during Development and in SMA
Aleksandra Vukojicic et al.
CELL REPORTS (2019)
AVXS-101 (Onasemnogene Abeparvovec) for SMA 1: Comparative Study with a Prospective Natural History Cohort
Samiah A. Al-Zaidy et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2019)
Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
Christian Hinderer et al.
HUMAN GENE THERAPY (2018)
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Erik Allen Lykken et al.
JOURNAL OF NEURODEVELOPMENTAL DISORDERS (2018)
Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape
Matthew J. A. Wood et al.
HUMAN MOLECULAR GENETICS (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiac pathology in spinal muscular atrophy: a systematic review
C. A. Wijngaarde et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Natural history of infantile-onset spinal muscular atrophy
Stephen J. Kolb et al.
ANNALS OF NEUROLOGY (2017)
Emerging Therapies and Challenges in Spinal Muscular Atrophy
Michelle A. Farrar et al.
ANNALS OF NEUROLOGY (2017)
A Large Animal Model of Spinal Muscular Atrophy and Correction of Phenotype
Sandra I. Duque et al.
ANNALS OF NEUROLOGY (2015)
Astrocytes influence the severity of spinal muscular atrophy
Hansjoerg Rindt et al.
HUMAN MOLECULAR GENETICS (2015)
Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose-response Study in Mice and Nonhuman Primates
Kathrin Meyer et al.
MOLECULAR THERAPY (2015)
Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies
R. T. Bartus et al.
NEUROBIOLOGY OF DISEASE (2015)
Observational study of spinal muscular atrophy type I and implications for clinical trials
Richard S. Finkel et al.
NEUROLOGY (2014)
Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I
Richard S. Finkel
NEUROMUSCULAR DISORDERS (2013)
Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer
George Buchlis et al.
BLOOD (2012)
Temporal requirement for high SMN expression in SMA mice
Thanh T. Le et al.
HUMAN MOLECULAR GENETICS (2011)
Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy
Cathleen M. Lutz et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric Disorders
Adam K. Bevan et al.
MOLECULAR THERAPY (2011)
Spinal muscular atrophy
Adele D'Amico et al.
ORPHANET JOURNAL OF RARE DISEASES (2011)
Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice
Christopher R. Heier et al.
HUMAN MOLECULAR GENETICS (2010)
Cardiac defects contribute to the pathology of spinal muscular atrophy models
Monir Shababi et al.
HUMAN MOLECULAR GENETICS (2010)
Early heart failure in the SMNΔ7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery
Adam K. Bevan et al.
HUMAN MOLECULAR GENETICS (2010)
The c.859G > C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor
S. Bernal et al.
JOURNAL OF MEDICAL GENETICS (2010)
A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene
Thomas W. Prior et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
Regulation of SMN Protein Stability
Barrington G. Burnett et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor Neurons
Sandra Duque et al.
MOLECULAR THERAPY (2009)
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Kevin D. Foust et al.
NATURE BIOTECHNOLOGY (2009)
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection
Carmela Zincarelli et al.
MOLECULAR THERAPY (2008)
Natural history of denervation in SMA:: Relation to age, SMN2 copy number, and function
KJ Swoboda et al.
ANNALS OF NEUROLOGY (2005)
Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo
Z Wang et al.
GENE THERAPY (2003)
Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1
L Cartegni et al.
NATURE GENETICS (2002)
Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR:: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy
M Feldkötter et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2
MD Mailman et al.
GENETICS IN MEDICINE (2002)
CMV-β-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1α promoter and results in therapeutic levels of human factor X in mice
LF Xu et al.
HUMAN GENE THERAPY (2001)
Share Paper
